AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer ...

TOKYO & BASKING RIDGE, N.J., May 07, 2025--(BUSINESS WIRE)--Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, ...

Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic ...

TOKYO & BASKING RIDGE, N.J., April 21, 2025--(BUSINESS WIRE)--Positive topline results from a planned interim analysis of the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

A new cancer drug called trastuzumab deruxtecan, also known as Enhertu, has just been approved in the UK. This drug is designed to help adults with certain types of advanced cancer that cannot be ...

Get Instant Summarized Text (Gist) Trastuzumab deruxtecan, known as Enhertu, has been approved in the UK for treating advanced HER2-positive cancers that are inoperable or have metastasized. This ...

Positive topline results from the DESTINY-Gastric04 phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in the primary ...